{"id":536259,"date":"2021-09-09T08:04:44","date_gmt":"2021-09-09T12:04:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-kicks-off-ovarian-cancer-awareness-month-by-further-establishing-itself-as-a-thought-leader-in-ovarian-cancer\/"},"modified":"2021-09-09T08:04:44","modified_gmt":"2021-09-09T12:04:44","slug":"aspira-womens-health-kicks-off-ovarian-cancer-awareness-month-by-further-establishing-itself-as-a-thought-leader-in-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-kicks-off-ovarian-cancer-awareness-month-by-further-establishing-itself-as-a-thought-leader-in-ovarian-cancer\/","title":{"rendered":"Aspira Women\u2019s Health Kicks Off Ovarian Cancer Awareness Month by Further Establishing Itself as a Thought Leader in Ovarian Cancer"},"content":{"rendered":"

\nSignals Call to Action for Immediate Progress in Conquering Ovarian Cancer
\n<\/h2>\n
\n

AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) — Heralding the beginning of Ovarian Cancer Awareness Month, Aspira Women\u2019s Health, Inc (\u201cAspira\u201d) (Nasdaq: AWH) will ring the closing bell at NASDAQ on Thursday, September 9, 2021 to signal a call to action for progress in ovarian cancer awareness, access to important risk assessment technology, and research. The closing bell ceremony will begin at approximately 3:45pm EDT. A livestream of the Nasdaq Closing Bell will be available at https:\/\/livestream.com\/nasdaq\/live<\/a><\/p>\n

Despite decades of research, ovarian cancer remains one of the most lethal of gynecological cancers. In the United States, it ranks as the fifth highest cause of cancer death in women, even though its incidence—1.3% of all new annual cancer cases\u2014is relatively low. Unfortunately, the onset of ovarian cancer is usually quite insidious, with symptoms that mimic much less serious conditions, thereby earning it the unsettling nickname of \u201cthe cancer that whispers.\u201d It actually does NOT whisper as women often ignore or dismiss the bloating, back pain, appetite loss, vaginal bleeding, or urinary disturbances that can be the \u201calarm bell\u201d that malignancy is present. In fact, many health care professionals exhibit the same response when alerted to these symptoms by women because they are so generic. The end result is that when ovarian cancer is finally detected in the majority of women, it has progressed to stage III or IV disease, when five-year survival rates can be as low as 27%.<\/p>\n

Aspira Women\u2019s Health Inc. has been increasing access for women to important risk assessment tools and building awareness of our company\u2019s solutions and its brand thru new guidelines, direct to provider education at the local, regional and national level including participating in a congressional briefing in March 2021 regarding the need to fund diversity trials and support MCIT breakthrough technology at the FDA as well as a presentation given by Kaile Zagger, our Chief Operating Officer, at a FemTech Industry Landscape in July 2021 titled \u201cChanging the story through transformation, A New Paradigm in Early Detection of Ovarian Cancer.\u201d<\/p>\n

During the month of September—Ovarian Cancer Awareness Month\u2014we are bringing awareness to our solutions and our mission to transform women\u2019s health by participating in and sponsoring several events.<\/p>\n

\n September 14-15 – Women\u2019s Health Innovation Summit,<\/strong> Boston, MA,<\/p>\n